237 results on '"Kiyotani K"'
Search Results
2. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations
- Author
-
Province, MA, Goetz, MP, Brauch, H, Flockhart, DA, Hebert, JM, Whaley, R, Suman, VJ, Schroth, W, Winter, S, Zembutsu, H, Mushiroda, T, Newman, WG, Lee, M‐T M, Ambrosone, CB, Beckmann, MW, Choi, J‐Y, Dieudonné, A‐S, Fasching, PA, Ferraldeschi, R, Gong, L, Haschke‐Becher, E, Howell, A, Jordan, LB, Hamann, U, Kiyotani, K, Krippl, P, Lambrechts, D, Latif, A, Langsenlehner, U, Lorizio, W, Neven, P, Nguyen, AT, Park, B‐W, Purdie, CA, Quinlan, P, Renner, W, Schmidt, M, Schwab, M, Shin, J‐G, Stingl, JC, Wegman, P, Wingren, S, Wu, AHB, Ziv, E, Zirpoli, G, Thompson, AM, Jordan, VC, Nakamura, Y, Altman, RB, Ames, MM, Weinshilboum, RM, Eichelbaum, M, Ingle, JN, Klein, TE, and Consortium, International Tamoxifen Pharmacogenomics
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Breast Cancer ,Women's Health ,Estrogen ,Aging ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Aged ,Antineoplastic Agents ,Hormonal ,Breast Neoplasms ,Cytochrome P-450 CYP2D6 ,Female ,Genetic Variation ,Genotype ,Humans ,Menopause ,Middle Aged ,Pharmacogenetics ,Survival Analysis ,Tamoxifen ,Treatment Outcome ,International Tamoxifen Pharmacogenomics Consortium ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.
- Published
- 2014
3. インド国高速鉄道の在来線近接施工区間のコンクリート構造物の設計業務
- Author
-
Kiyotani, K., primary
- Published
- 2023
- Full Text
- View/download PDF
4. 265P Tumor-agonistic genomic profiling
- Author
-
Hayashi, N., primary, Fukada, I., additional, Ohmoto, A., additional, Hosonaga, M., additional, Wang, X., additional, Yamazaki, M., additional, Ueki, A., additional, Kiyotani, K., additional, Tonooka, A., additional, Takeuchi, K., additional, Mori, S., additional, and Takahashi, S., additional
- Published
- 2022
- Full Text
- View/download PDF
5. 1554P Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2- positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy
- Author
-
Shoji, H., Wakatsuki, T., Takahari, D., Yamamoto, N., Ooki, A., Chin, K., Kurihara, N., Kiyotani, K., Mashima, T., Ogura, M., Nakayama, I., Minashi, K., Hara, H., Shinozaki, E., Ishizuka, N., Kitano, S., Seimiya, H., Takeuchi, K., Boku, N., and Yamaguchi, K.
- Published
- 2023
- Full Text
- View/download PDF
6. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients
- Author
-
Yew, P Y, Alachkar, H, Yamaguchi, R, Kiyotani, K, Fang, H, Yap, K L, Liu, H T, Wickrema, A, Artz, A, van Besien, K, Imoto, S, Miyano, S, Bishop, M R, Stock, W, and Nakamura, Y
- Published
- 2015
- Full Text
- View/download PDF
7. Attenuation of a field Sendai virus isolate through egg-passages is associated with an impediment of viral genome replication in mouse respiratory cells
- Author
-
Kiyotani, K., Sakaguchi, T., Fujii, Y., and Yoshida, T.
- Published
- 2001
- Full Text
- View/download PDF
8. Endogenous protease-dependent replication of human influenza viruses in two MDCK cell lines
- Author
-
Noma, K., Kiyotani, K., Kouchi, H., Fujii, Y., Egi, Y., Tanaka, K., and Yoshida, T.
- Published
- 1998
- Full Text
- View/download PDF
9. A field isolate of Sendai virus: its high virulence to mice and genetic divergence from prototype strains
- Author
-
Sakaguchi, T., Kiyotani, K., Sakaki, M., Fujii, Y., and Yoshida, T.
- Published
- 1994
- Full Text
- View/download PDF
10. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer
- Author
-
Akiyoshi, T, primary, Tanaka, N, additional, Kiyotani, K, additional, Gotoh, O, additional, Yamamoto, N, additional, Oba, K, additional, Fukunaga, Y, additional, Ueno, M, additional, and Mori, S, additional
- Published
- 2019
- Full Text
- View/download PDF
11. 546 Immune biomarkers to predict response of nivolumab, intratumoral gene expression and T cell receptor repertoire analysis
- Author
-
Fukushima, S., primary, Inoue, H., additional, Park, J., additional, Kiyotani, K., additional, Kiniwa, Y., additional, Fujisawa, Y., additional, Kato, H., additional, Asai, J., additional, Yokota, K., additional, Ihn, H., additional, and Nakamura, Y., additional
- Published
- 2017
- Full Text
- View/download PDF
12. 453 T cell receptor repertoire analysis in the melanoma patient with myasthenic crisis and polymyositis induced by nivolumab
- Author
-
Fukushima, S., primary, Kimura, T., additional, Miyashita, A., additional, Aoi, J., additional, Jinnin, M., additional, Inoue, H., additional, Kiyotani, K., additional, Park, J., additional, Nakamura, Y., additional, and Ihn, H., additional
- Published
- 2016
- Full Text
- View/download PDF
13. Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity
- Author
-
Yamada, A, primary, Maeda, K, additional, Kiyotani, K, additional, Mushiroda, T, additional, Nakamura, Y, additional, and Sugiyama, Y, additional
- Published
- 2014
- Full Text
- View/download PDF
14. Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring
- Author
-
Aomori, T., primary, Fujita, Y., additional, Obayashi, K., additional, Sato, H., additional, Kiyotani, K., additional, Nakamura, K., additional, Nakamura, T., additional, and Yamamoto, K., additional
- Published
- 2014
- Full Text
- View/download PDF
15. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- Author
-
Province, M A, primary, Goetz, M P, additional, Brauch, H, additional, Flockhart, D A, additional, Hebert, J M, additional, Whaley, R, additional, Suman, V J, additional, Schroth, W, additional, Winter, S, additional, Zembutsu, H, additional, Mushiroda, T, additional, Newman, W G, additional, Lee, M-T M, additional, Ambrosone, C B, additional, Beckmann, M W, additional, Choi, J-Y, additional, Dieudonné, A-S, additional, Fasching, P A, additional, Ferraldeschi, R, additional, Gong, L, additional, Haschke-Becher, E, additional, Howell, A, additional, Jordan, L B, additional, Hamann, U, additional, Kiyotani, K, additional, Krippl, P, additional, Lambrechts, D, additional, Latif, A, additional, Langsenlehner, U, additional, Lorizio, W, additional, Neven, P, additional, Nguyen, A T, additional, Park, B-W, additional, Purdie, C A, additional, Quinlan, P, additional, Renner, W, additional, Schmidt, M, additional, Schwab, M, additional, Shin, J-G, additional, Stingl, J C, additional, Wegman, P, additional, Wingren, S, additional, Wu, A H B, additional, Ziv, E, additional, Zirpoli, G, additional, Thompson, A M, additional, Jordan, V C, additional, Nakamura, Y, additional, Altman, R B, additional, Ames, M M, additional, Weinshilboum, R M, additional, Eichelbaum, M, additional, Ingle, J N, additional, and Klein, T E, additional
- Published
- 2013
- Full Text
- View/download PDF
16. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers
- Author
-
Yamaori, S, primary, Yamazaki, H, additional, Iwano, S, additional, Kiyotani, K., additional, Matsumura, K., additional, Saito, T, additional, Parkinson, A., additional, Nakagawa, K., additional, and Kamataki, T, additional
- Published
- 2005
- Full Text
- View/download PDF
17. Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis
- Author
-
Kato, A, primary, Kiyotani, K, additional, Sakai, Y, additional, Yoshida, T, additional, Shioda, T, additional, and Nagai, Y, additional
- Published
- 1997
- Full Text
- View/download PDF
18. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses
- Author
-
Takao, S I, primary, Kiyotani, K, additional, Sakaguchi, T, additional, Fujii, Y, additional, Seno, M, additional, and Yoshida, T, additional
- Published
- 1997
- Full Text
- View/download PDF
19. Correlation of proteolytic cleavage of F protein precursors in paramyxoviruses with expression of the fur, PACE4 and PC6 genes in mammalian cells
- Author
-
Sakaguchi, T., primary, Fujii, Y., additional, Kiyotani, K., additional, and Yoshida, T., additional
- Published
- 1994
- Full Text
- View/download PDF
20. Sendai virus pneumonia: evidence for the early recruitment of gamma delta T cells during the disease course
- Author
-
Ogasawara, T, primary, Emoto, M, additional, Kiyotani, K, additional, Shimokata, K, additional, Yoshida, T, additional, Nagai, Y, additional, and Yoshikai, Y, additional
- Published
- 1994
- Full Text
- View/download PDF
21. F0-containing noninfectious Sendai virus can initiate replication in mouse lungs but requires a relatively long incubation period
- Author
-
Kiyotani, K, primary, Sakaguchi, T, additional, Fujii, Y, additional, and Yoshida, T, additional
- Published
- 1993
- Full Text
- View/download PDF
22. Expression of the HN, F, NP and M proteins of Sendai virus by recombinant vaccinia viruses and their contribution to protective immunity against Sendai virus infections in mice
- Author
-
Sakaguchi, T., primary, Takao, S.-i., additional, Kiyotani, K., additional, Fujii, Y., additional, Nakayama, T., additional, and Yoshida, T., additional
- Published
- 1993
- Full Text
- View/download PDF
23. Distribution and substrate specificity of intracellular proteolytic processing enzyme(s) for paramyxovirus fusion glycoproteins
- Author
-
Kawahara, N., primary, Yang, X. Z., additional, Sakaguchi, T., additional, Kiyotani, K., additional, Nagai, Y., additional, and Yoshida, T., additional
- Published
- 1992
- Full Text
- View/download PDF
24. Detection of cytomegalovirus in urine samples by an enzyme-linked immunosorbent assay using a monoclonal antibody against the viral 150-kilodalton protein
- Author
-
Yamanaka, T, primary, Kiyotani, K, additional, Sakaguchi, T, additional, Fukuda, Y, additional, Dohi, K, additional, Yamada, M, additional, Yoshida, M, additional, Nii, S, additional, and Yoshida, T, additional
- Published
- 1992
- Full Text
- View/download PDF
25. STUDIES ON YERSINIA PSEUDOTUBERCULOSIS : III. A METHOD FOR ISOLATION OF Y.PSEUDOTUBERCULOSIS FROM FECES
- Author
-
Kiyotani K, Misao Tsubokura, and Keizaburo Itagaki
- Subjects
General Medicine ,Biology ,Isolation (microbiology) ,Yersinia pseudotuberculosis 3 ,Microbiology - Published
- 1973
26. In Vitro Properties of Mycobacterium lepraemurium Strain Keishicho
- Author
-
SAITO, H., primary, YAMAOKA, K., additional, and KIYOTANI, K., additional
- Published
- 1976
- Full Text
- View/download PDF
27. CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy.
- Author
-
Wolf SP, Leisegang M, Steiner M, Wallace V, Kiyotani K, Hu Y, Rosenberger L, Huang J, Schreiber K, Nakamura Y, Schietinger A, and Schreiber H
- Subjects
- Animals, Mice, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell genetics, Mice, Inbred C57BL, Humans, Mice, Transgenic, Female, Recombination, Genetic immunology, CD4-Positive T-Lymphocytes immunology, Immunotherapy, Adoptive methods
- Abstract
Cancers eventually kill hosts even when infiltrated by cancer-specific T cells. We examined whether cancer-specific T cell receptors of CD4
+ T cells (CD4TCRs) from tumor-bearing hosts can be exploited for adoptive TCR therapy. We focused on CD4TCRs targeting an autochthonous mutant neoantigen that is only presented by stroma surrounding the MHC class II-negative cancer cells. The 11 most common tetramer-sorted CD4TCRs were tested using TCR-engineered CD4+ T cells. Three TCRs were characterized by convergent recombination for which multiple T cell clonotypes differed in their nucleotide sequences but encoded identical TCR α and β chains. These preferentially selected TCRs destroyed tumors equally well and halted progression through reprogramming of the tumor stroma. TCRs represented by single T cell clonotypes were similarly effective only if they shared CDR elements with preferentially selected TCRs in both α and β chains. Selecting candidate TCRs on the basis of these characteristics can help identify TCRs that are potentially therapeutically effective.- Published
- 2024
- Full Text
- View/download PDF
28. Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.
- Author
-
Ito M, Koido S, Iwamoto T, Morimoto S, Fujiki F, Sugiyama H, Matsumoto S, Effenberger C, Kiyotani K, and Shiba K
- Subjects
- Humans, Cell Line, Tumor, Epitopes immunology, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes drug effects, HLA-A24 Antigen immunology, Mesothelioma, Malignant immunology, Mesothelioma, Malignant drug therapy, Epitopes, T-Lymphocyte immunology, Oligopeptides, WT1 Proteins immunology, Proteasome Inhibitors pharmacology, Proteasome Endopeptidase Complex metabolism, Proteasome Endopeptidase Complex immunology, Mesothelioma immunology, Mesothelioma drug therapy
- Abstract
The immunogenicity of cancer cells is influenced by several factors, including the expression of the major histocompatibility complex class I (MHC-I), antigen expression, and the repertoire of proteasome-produced epitope peptides. The malignant pleural mesothelioma cell line ACC-MEOS-4 (MESO-4) expresses high levels of MHC-I and Wilms tumor 1 (WT1) tumor antigens. Using a functional T cell reporter assay specific for the HLA-A*24:02 restricted WT1 epitope (WT1235, CMTWNQMNL), we searched for factors that augmented the immunogenicity of MESO-4, focusing on proteasomes, which have a central role in the antigen processing machinery. ONX-0914, a selective inhibitor of the immunoproteasome subunit β5i, enhanced immunogenicity dose-dependently at low concentrations without cytotoxicity. In addition, CD8+ T lymphocytes recognizing WT1 showed greater cytotoxicity against MESO-4 pre-treated with ONX-0914. MESO-4 expresses a standard proteasome (SP) and immunoproteasome (IP). Notably, IP has distinct catalytic activity from SP, favoring the generation of antigenic peptides with high affinity for MHC-I in antigen-presenting cells and cancer cells. In vitro, immunoproteasome digestion assay and mass spectrometry analysis showed that IP cleaved WT1235 internally after the hydrophobic residues. Importantly, this internal cleavage of the WT1235 epitope was mitigated by ONX-0914. These results suggest that ONX-0914 prevents the internal destructive cleavage of WT1235 by IP, thereby promoting the specific presentation of the WT1 epitope by MESO-4. In conclusion, selective IP inhibitors might offer a means to modulate cancer cell immunogenicity by directing the presentation of particular tumor epitopes., Competing Interests: K. Kiyotani is a scientific advisor of Cancer Precision Medicine, Inc. No disclosures were reported by the other authors. We have confirmed that our adherence to all PLOS ONE policies on data and material sharing remains unchanged., (Copyright: © 2024 Ito et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
29. Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes.
- Author
-
Okamura K, Wang L, Nagayama S, Yamashita M, Tate T, Matsumoto S, Takamatsu M, Kitano S, Kiyotani K, and Nakamura Y
- Subjects
- Humans, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Male, Female, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, Aged, Receptors, Antigen, T-Cell metabolism, Receptors, Antigen, T-Cell genetics, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Middle Aged, Colorectal Neoplasms immunology, Colorectal Neoplasms pathology, Lymph Nodes immunology, Lymph Nodes pathology, Tumor Microenvironment immunology
- Abstract
TCRαβ+ CD4- CD8- double-negative T (DNT) cells are minor populations in peripheral blood, and their roles have mostly been discussed in inflammation and autoimmunity. However, the functions of DNT cells in tumor microenvironment remain to be elucidated. We investigated their characteristics, possible origins and functions in colorectal cancer tissues as well as their corresponding tumor-draining lymph nodes. We found a significant enrichment of DNT cells in tumor tissues compared with their corresponding lymph nodes, especially in tumors with lower T cell infiltration. T cell receptor (TCR) sequence analysis of CD4+ T, CD8+ T and DNT cells indicated that TCR sequences detected in DNT cells were found in CD8+ T cells, but rarely in CD4+ T cells, suggesting that a part of DNT cells was likely to be originated from CD8+ T cells. Through a single-cell transcriptomic analysis of DNT cells, we found that a DNT cell cluster, which showed similar phenotypes to central memory CD8+ T cells with low expression of effector and exhaustion markers, revealed some specific gene expression patterns, including higher GZMK expression. Moreover, in flow cytometry analysis, we found that DNT cells lost production of cytotoxic mediators. These findings imply that DNT cells might function as negative regulators of anti-tumor immune responses in tumor microenvironment., Competing Interests: KK is a scientific advisor of Cancer Precision Medicine, Inc. YN is a stockholder and a scientific advisor of OncoTherapy Science, Inc., (© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2024
- Full Text
- View/download PDF
30. Identification of RNF213 as a Potential Suppressor of Local Invasion in Intrahepatic Cholangiocarcinoma.
- Author
-
Chiablaem K, Jinawath A, Nuanpirom J, Arora JK, Nasaree S, Thanomchard T, Singhto N, Chittavanich P, Suktitipat B, Charoensawan V, Chairoungdua A, Jinn-Chyuan Sheu J, Kiyotani K, Svasti J, Nakamura Y, and Jinawath N
- Subjects
- Humans, Cell Line, Tumor, Male, Female, Middle Aged, Adenosine Triphosphatases metabolism, Adenosine Triphosphatases genetics, Aged, Cell Movement genetics, Cholangiocarcinoma genetics, Cholangiocarcinoma pathology, Cholangiocarcinoma metabolism, Ubiquitin-Protein Ligases genetics, Ubiquitin-Protein Ligases metabolism, Bile Duct Neoplasms genetics, Bile Duct Neoplasms pathology, Bile Duct Neoplasms metabolism, Neoplasm Invasiveness
- Abstract
Intrahepatic cholangiocarcinoma (ICC) is a lethal cancer with poor survival especially when it spreads. The histopathology of its rare intraductal papillary neoplasm of the bile duct type (IPNB) characteristically shows cancer cells originating within the confined bile duct space. These cells eventually invade and infiltrate the nearby liver tissues, making it a good model to study the mechanism of local invasion, which is the earliest step of metastasis. To discover potential suppressor genes of local invasion in ICC, we analyzed the somatic mutation profiles and performed clonal evolution analyses of the 11 pairs of macrodissected locally invasive IPNB tissues (LI-IPNB) and IPNB tissues without local invasion from the same patients. We identified a protein-truncating variant in an E3 ubiquitin ligase, RNF213 (c.6967C>T; p.Gln2323X; chr17: 78,319,102 [hg19], exon 29), as the most common protein-truncating variant event in LI-IPNB samples (4/11 patients). Knockdown of RNF213 in HuCCT1 and YSCCC cells showed increased migration and invasion, and reduced vasculogenic mimicry but maintained normal proliferation. Transcriptomic analysis of the RNF213-knockdown vs control cells was then performed in the HuCCT1, YSCCC, and KKU-100 cells. Gene ontology enrichment analysis of the common differentially expressed genes revealed significantly altered cytokine and oxidoreductase-oxidizing metal ion activities, as confirmed by Western blotting. Gene Set Enrichment Analysis identified the most enriched pathways being oxidative phosphorylation, fatty acid metabolism, reactive oxygen species, adipogenesis, and angiogenesis. In sum, loss-of-function mutation of RNF213 is a common genetic alteration in LI-IPNB tissues. RNF213 knockdown leads to increased migration and invasion of ICC cells, potentially through malfunctions of the pathways related to inflammation and energy metabolisms., (Copyright © 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Availability of genome-matched therapy based on clinical practice.
- Author
-
Hayashi N, Mori S, Ohmoto A, Fukada I, Yamazaki M, Hosonaga M, Wang X, Ueki A, Kiyotani K, Tonooka A, Takeuchi K, and Takahashi S
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Genomics methods, Precision Medicine, Aged, 80 and over, Sarcoma genetics, Sarcoma therapy, Neoplasms genetics, Neoplasms therapy
- Abstract
Background: Comprehensive genomic profiling (CGP) provides new opportunities for patients with advanced cancer to receive genome-matched therapies, but the availability rate of these remains low. We reviewed our CGP cases and suggested possible strategies to improve the current status from a clinical perspective., Methods: Druggable genomic alterations and barriers to accessing genome-matched therapies were investigated in 653 patients with 30 various types of cancers who underwent CGP., Results: While the availability rate of genome-matched therapies as a whole was 9.5%, CGP was useful in some cancer types. Patients with thyroid cancer and lung cancer harbored druggable genomic alterations at high rates, while sarcoma rarely harbored these alterations (100%, 76%, and 15.2%, respectively). In contrast, the availability rate of genome-matched therapies was highest in patients with sarcoma and head and neck cancer (HNC) (60% and 40%, respectively). One hundred thirteen patients (63.5%) had multiple barriers to accessing genome-matched therapy. Of 178 patients, 21 patients (11.8%) could not be considered for genome-matched therapies solely because of the deterioration of their performance status., Conclusion: This study demonstrated the usefulness of CGP for patients with sarcoma and HNC in addition to lung cancer in clinical practice. Performing CGP at the front line has the potential to improve the availability of genome-matched therapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
32. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
- Author
-
Wolf SP, Anastasopoulou V, Drousch K, Diehl MI, Engels B, Yew PY, Kiyotani K, Nakamura Y, Schreiber K, Schreiber H, and Leisegang M
- Subjects
- Humans, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Receptors, Antigen, T-Cell genetics, Immunotherapy, Adoptive methods, Antigens, Neoplasm immunology, Neoplasms immunology, Neoplasms therapy
- Abstract
Purpose: To achieve eradication of solid tumors, we examined how many neoantigens need to be targeted with how many T-cell receptors (TCR) by which type of T cells., Experimental Design: Unmanipulated, naturally expressed (autochthonous) neoantigens were targeted with adoptively transferred TCR-engineered autologous T cells (TCR-therapy). TCR-therapy used CD8+ T-cell subsets engineered with TCRs isolated from CD8+ T cells (CD8+TCR-therapy), CD4+ T-cell subsets engineered with TCRs isolated from CD4+ T cells (CD4+TCR-therapy), or combinations of both. The targeted tumors were established for at least 3 weeks and derived from primary autochthonous cancer cell cultures, resembling natural solid tumors and their heterogeneity as found in humans., Results: Relapse was common with CD8+TCR-therapy even when targeting multiple different autochthonous neoantigens on heterogeneous solid tumors. CD8+TCR-therapy was only effective against homogenous tumors artificially derived from a cancer cell clone. In contrast, a combination of CD8+TCR-therapy with CD4+TCR-therapy, each targeting one neoantigen, eradicated large and established solid tumors of natural heterogeneity. CD4+TCR-therapy targeted a mutant neoantigen on tumor stroma while direct cancer cell recognition by CD8+TCR-therapy was essential for cure. In vitro data were consistent with elimination of cancer cells requiring a four-cell cluster composed of TCR-engineered CD4+ and CD8+ T cells together with antigen-presenting cells and cancer cells., Conclusions: Two cancer-specific TCRs can be essential and sufficient to eradicate heterogeneous solid tumors expressing unmanipulated, autochthonous targets. We demonstrate that simplifications to adoptive TCR-therapy are possible without compromising efficacy., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
33. Clinical landscape of TP73 structural variants in ATL patients.
- Author
-
Hiramatsu H, Yokomori R, Shengyi L, Tanaka N, Mori S, Kiyotani K, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Sanda T, and Ishida T
- Subjects
- Humans, Tumor Protein p73 genetics, Genes, Tumor Suppressor, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Cell Proliferation, RNA, Long Noncoding, MicroRNAs
- Published
- 2023
- Full Text
- View/download PDF
34. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.
- Author
-
Fukada I, Mori S, Hayashi N, Hosonaga M, Xiaofei W, Yamazaki M, Ueki A, Kiyotani K, Tonooka A, Takeuchi K, Ueno T, and Takahashi S
- Subjects
- Male, Female, Humans, Middle Aged, Prognosis, Retrospective Studies, Mutation, Genomics methods, Neoplasms genetics, Neoplasms, Second Primary
- Abstract
Cancer genomic profile (CGP) testing, which is covered by the national health insurance system in Japan, has been introduced as a routine clinical practice. However, the effects of CGP testing on prognoses remain unclear. Drug accessibility rates and prognoses after CGP testing were retrospectively investigated in 713 patients who underwent CGP testing examined by our molecular tumor board between November 2019 and October 2022,. Overall survival (OS) was examined using the log-rank test and the Kaplan-Meier method. The median age of patients (326 males and 387 females) was 58 years (12-85 years). CGP testing revealed one or more gene mutations in 681 cases (95.5%), among which actionable gene mutations were detected in 439 (61.6%). Although treatment options were recommended for 285 cases (40.0%) by the molecular tumor board, only 45 received treatment based on their gene mutations. During the median observation period of 8.6 months, 351 (49.2%) patients died of the exacerbation of existing diseases. No significant differences were observed in OS between patients treated with and without genomically matched therapy (p = 0.285). According to clinical responses to treatment based on gene mutations, median OS was significantly longer in patients who achieved partial response and stable disease (26.5 months; 95% CI 14.4-38.6) than in those with progressive disease and not evaluated (9.8 months; 95% CI 5.8-13.8, p = 0.013). Responses to treatment based on gene mutations may improve prognoses, and it is important to increase the drug accessibility rate after CGP testing., (© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2023
- Full Text
- View/download PDF
35. Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine.
- Author
-
Morisaki S, Onishi H, Morisaki T, Kubo M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Tsujimura K, Yoshimura S, Yew PY, Kiyotani K, Nakamura Y, Nakamura M, Kitazono T, and Morisaki T
- Subjects
- Humans, Antigens, Neoplasm, Peptides, Epitopes, Dendritic Cells, CD8-Positive T-Lymphocytes, Neoplasms
- Abstract
Neoantigens/ are tumor-specific antigens that evade central immune tolerance mechanisms in the thymus. Long-term tumor-specific cytotoxic T lymphocyte activity maintenance requires class II antigen-reactive CD4
+ T cells. We had previously shown that intranodal vaccination with class I neoantigen peptide-pulsed dendritic cells (DCs) induced a robust immune response in a subset of patients with metastatic cancer. The present study aimed to perform a detailed ex vivo analysis of immune responses in four patients receiving an intranodal hybrid human leukocyte antigen class II neoantigen peptide encompassing a class I neoantigen epitope (hybrid neoantigen)-pulsed DC vaccine. After vaccination, strong T-cell reactions against the hybrid class II peptide and the class I-binding neoantigen peptide were observed in all four patients. We found that hybrid class II neoantigen peptide-pulsed DCs stimulated CD4+ T cells via direct antigen presentation and CD8+ T cells via cross-presentation. Further, we demonstrated that hybrid class II peptides encompassing multiple class I neoantigen epitope-pulsed DCs could present multiple class I peptides to CD8+ T cells via cross-presentation. Our findings provide insight into the mechanisms underlying hybrid neoantigen-pulsed DC vaccine therapy and suggest future neoantigen vaccine design., Competing Interests: Authors PYY and SY are employees of Cancer Precision Medicine Inc. KK is scientific advisor of cancer Precision Medicine, Inc. YN is a stockholder and a scientific advisor of Oncotherapy Science, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Morisaki, Onishi, Morisaki, Kubo, Umebayashi, Tanaka, Koya, Nakagawa, Tsujimura, Yoshimura, Yew, Kiyotani, Nakamura, Nakamura, Kitazono and Morisaki.)- Published
- 2023
- Full Text
- View/download PDF
36. Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer.
- Author
-
Haraguchi M, Kiyotani K, Tate T, Sakata S, Sagawa R, Takagi S, Nagayama S, Takeuchi K, Takahashi K, and Katayama R
- Subjects
- Humans, Animals, Mice, Memory T Cells, Disease Models, Animal, CD8-Positive T-Lymphocytes, Receptors, Antigen, T-Cell, Tumor Microenvironment, Colonic Neoplasms, Rectal Neoplasms
- Abstract
Immune checkpoint inhibitors (ICIs) have shown superior clinical responses and significantly prolong overall survival (OS) for many types of cancer. However, some patients exhibit long-term OS, whereas others do not respond to ICI therapy at all. To develop more effective and long-lasting ICI therapy, understanding the host immune response to tumors and the development of biomarkers are imperative. In this study, we established an MC38 immunological memory mouse model by administering an anti-PD-L1 antibody and evaluating the detailed characteristics of the immune microenvironment including the T cell receptor (TCR) repertoire. In addition, we found that the memory mouse can be established by surgical resection of residual tumor following anti-PD-L1 antibody treatment with a success rate of > 40%. In this model, specific depletion of CD8 T cells revealed that they were responsible for the rejection of reinoculated MC38 cells. Analysis of the tumor microenvironment (TME) of memory mice using RNA-seq and flow cytometry revealed that memory mice had a quick and robust immune response to MC38 cells compared with naïve mice. A TCR repertoire analysis indicated that T cells with a specific TCR repertoire were expanded in the TME, systemically distributed, and preserved in the host for a long time period. We also identified shared TCR clonotypes between serially resected tumors in patients with colorectal cancer (CRC). Our results suggest that memory T cells are widely preserved in patients with CRC, and the MC38 memory model is potentially useful for the analysis of systemic memory T-cell behavior., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
37. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
- Author
-
Tate T, Matsumoto S, Nemoto K, Leisegang M, Nagayama S, Obama K, Nakamura Y, and Kiyotani K
- Abstract
Immunotherapies, including immune checkpoint blockades, play a critically important role in cancer treatments. For immunotherapies, neoantigens, which are generated by somatic mutations in cancer cells, are thought to be good targets due to their tumor specificity. Because neoantigens are unique in individual cancers, it is challenging to develop personalized immunotherapy targeting neoantigens. In this study, we screened "shared neoantigens", which are specific types of neoantigens derived from mutations observed commonly in a subset of cancer patients. Using exome sequencing data in the Cancer Genome Atlas (TCGA), we predicted shared neoantigen peptides and performed in vitro screening of shared neoantigen-reactive CD8
+ T cells using peripheral blood from healthy donors. We examined the functional activity of neoantigen-specific T cell receptors (TCRs) by generating TCR-engineered T cells. Among the predicted shared neoantigens from TCGA data, we found that the mutated FGFR3Y373C peptide induced antigen-specific CD8+ T cells from the donor with HLA-A*02:06 via an ELISPOT assay. Subsequently, we obtained FGFR3Y373C -specific CD8+ T cell clones and identified two different sets of TCRs specifically reactive to FGFR3Y373C . We found that the TCR-engineered T cells expressing FGFR3Y373C -specific TCRs recognized the mutated FGFR3Y373C peptide but not the corresponding wild-type peptide. These two FGFR3Y373C -specific TCR-engineered T cells showed cytotoxic activity against mutated FGFR3Y373C -loaded cells. These results imply the possibility of strategies of immunotherapies targeting shared neoantigens, including cancer vaccines and TCR-engineered T cell therapies.- Published
- 2023
- Full Text
- View/download PDF
38. Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer.
- Author
-
Xu M, Tsunedomi R, Kiyotani K, Tomochika S, Furuya K, Nakajima M, Matsui H, Tokumitsu Y, Shindo Y, Yoshida S, Iida M, Suzuki N, Takeda S, Ioka T, Hazama S, and Nagano H
- Subjects
- Humans, T-Lymphocytes, Antibodies, Monoclonal pharmacology, Receptors, Antigen, T-Cell, alpha-beta, Receptors, Antigen, T-Cell, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy, Liver Neoplasms drug therapy
- Abstract
Background/aim: Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies (mAb) is widely used to treat patients with metastatic colorectal cancer (mCRC). Here, we investigated the effects of these antibodies on T-cell infiltration and T-cell receptor (TCR) repertoire variation in CRC liver metastases., Materials and Methods: Ten patients with mCRC received chemotherapy in combination with anti-EGFR (n=6) or anti-VEGF (n=4) mAb. T-cell infiltration was examined for CD3 and CD8 by carrying out immunohistochemistry on biopsy or surgical specimens from liver metastases before and after treatment. TCR repertoire analysis was carried out on specimens with post-treatment CD3
+ T-cell infiltration., Results: T-cell infiltrations were approximately 83% (5/6) and 50% (2/4), following treatment with anti-EGFR or anti-VEGF mAb, respectively. TCR repertoire analysis revealed higher clonality and lower diversity of TCR alpha and beta (TRA and TRB) in the anti-VEGF mAb group than that in the anti-EGFR group mAb. Furthermore, the percentage of the common TCR clones between infiltrating T cells and T cells in peripheral blood was significantly lower in the anti-VEGF mAb group compared to that in the anti-EGFR mAb group., Conclusion: The population of T cells infiltrating liver metastases in the anti-VEGF mAb group differed from that in the anti-EGFR mAb group., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
39. Druggable gene alterations in Japanese patients with rare malignancy.
- Author
-
Ohmoto A, Hayashi N, Fukada I, Yamazaki M, Yunokawa M, Kasuga A, Shinozaki E, Ueki A, Tonooka A, Takeuchi K, Mori S, Kiyotani K, and Takahashi S
- Subjects
- Biomarkers, Tumor genetics, Class I Phosphatidylinositol 3-Kinases genetics, Female, Humans, Japan epidemiology, Microsatellite Instability, Mutation, Precision Medicine, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Neoplasms genetics, Neoplasms pathology
- Abstract
Without a current standard of care, patients with rare malignancy are subjected to precision oncology with next-generation sequencing to identify a course of treatment. We sought to establish the clinical relevance of comprehensive genomic profiling (CGP) among patients with rare malignancy. Rare malignancy was defined using the Rare Cancers in Europe definition (<6 cases per 100,000 individuals). We analyzed gene mutations, fusions, tumor mutational burden (TMB), and microsatellite instability (MSI) status. Level A gene alterations, categorized using Clinical Interpretations of Variants in Cancer and MD Anderson Knowledge Base for Precision Oncology, were considered druggable. Rare malignancy accounted for 149 (45%) cases, with female genital cancers (32%) most common. Among the rare malignancy cases, we identified a lower frequency of mutation in TP53 (41% vs. 60%, P<0.001), KRAS (13% vs. 43%, P<0.001) and APC (3% vs. 25%, P<0.001), and a higher frequency of ARID1A mutation (14% vs. 6%, P=0.03), as compared with common malignancies. TMB-high and MSI-high cases were found in 8% and 2% of cases, respectively. Druggable alterations were detected in 37 patients with rare malignancy; this percentage tended to be higher than that for patients with common malignancies (25% vs. 17%, P=0.08). Common druggable alterations were BRAF V600E, ERBB2 amplification, PIK3CA E542K, and BRCA1/2 variant. Five of the 37 patients with druggable alterations received genome-driven treatment. There was no significant difference in overall survival between the rare and common malignancy groups. Our results provide clues for future clinical development and treatment success among Japanese patients with rare cancers., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
40. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
- Author
-
Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, and Ishida T
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, CD28 Antigens, DNA Copy Number Variations, Genomics, Homozygote, Humans, Nucleotides, Receptors, CCR7, Sequence Deletion, Treatment Outcome, Leukemia-Lymphoma, Adult T-Cell drug therapy, Leukemia-Lymphoma, Adult T-Cell genetics, Leukemia-Lymphoma, Adult T-Cell pathology, Lymphoma
- Abstract
In order to identify genomic biomarkers for the outcome of mogamulizumab-containing treatment, an integrated molecular analysis of adult T-cell leukemia/lymphoma (ATL) was conducted on 64 mogamulizumab-naïve patients. Among driver genes, CCR4 and CCR7 alterations were observed in 22% and 11% of the patients, respectively, both consisting of single nucleotide variants (SNV)/insertion-deletions (indels) in the C-terminus. Patients with CCR4 alterations or without CCR7 alterations exhibited a more favorable clinical response (complete response [CR] rate 93%, 13/14; P=0.024, and CR rate 71%, 40/56; P=0.036, respectively). Additionally, TP53, CD28, and CD274 alterations were identified in 35%, 16%, and 10% of the patients, respectively. TP53 alterations included SNV/indels or copy number variations (CNV) such as homozygous deletion; CD28 alterations included SNV, CNV such as amplification, or fusion; CD274 alterations included CNV such as amplification, or structural variants. Univariate analysis revealed that TP53, CD28 or CD274 alterations were associated with worse overall survival (OS) (hazard ratio [HR]: 2.330, 95% confidence interval [CI]: 1.183-4.589; HR: 3.191, 95% CI: 1.287- 7.911; HR: 3.301, 95% CI: 1.130-9.641, respectively) but that CCR4 alterations were associated with better OS (HR: 0.286, 95% CI: 0.087-0.933). Multivariate analysis indicated that in addition to performance status, TP53, CCR4 or CD274 alterations (HR: 2.467, 95% CI: 1.197-5.085; HR: 0.155, 95% CI: 0.031-0.778; HR: 14.393, 95% CI: 2.437-85.005, respectively) were independently and significantly associated with OS. The present study contributes to the establishment of precision medicine using mogamulizumab in ATL patients.
- Published
- 2022
- Full Text
- View/download PDF
41. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.
- Author
-
Minegishi Y, Kiyotani K, Nemoto K, Inoue Y, Haga Y, Fujii R, Saichi N, Nagayama S, and Ueda K
- Subjects
- Histocompatibility Antigens Class I, Humans, Mass Spectrometry methods, Mutation, Peptides chemistry, Proto-Oncogene Proteins p21(ras) genetics, Colorectal Neoplasms genetics, Ion Mobility Spectrometry methods
- Abstract
Understanding the properties of human leukocyte antigen (HLA) peptides (immunopeptides) is essential for precision cancer medicine, while the direct identification of immunopeptides from small biopsies of clinical tissues by mass spectrometry (MS) is still confronted with technical challenges. Here, to overcome these hindrances, high-field asymmetric waveform ion mobility spectrometry (FAIMS) is introduced to conduct differential ion mobility (DIM)-MS by seamless gas-phase fractionation optimal for scarce samples. By established DIM-MS for immunopeptidomics analysis, on average, 42.9 mg of normal and tumor colorectal tissues from identical patients (n = 17) were analyzed, and on average 4921 immunopeptides were identified. Among these 44,815 unique immunopeptides, two neoantigens, KRAS-G12V and CPPED1-R228Q, were identified. These neoantigens were confirmed by synthetic peptides through targeted MS in parallel reaction monitoring (PRM) mode. Comparison of the tissue-based personal immunopeptidome revealed tumor-specific processing of immunopeptides. Since the direct identification of neoantigens from tumor tissues suggested that more potential neoantigens have yet to be identified, we screened cell lines with known oncogenic KRAS mutations and identified 2 more neoantigens that carry KRAS-G12V. These results indicated that the established FAIMS-assisted DIM-MS is effective in the identification of immunopeptides and potential recurrent neoantigens directly from scarce samples such as clinical tissues., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
42. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy.
- Author
-
Okamura K, Nagayama S, Tate T, Chan HT, Kiyotani K, and Nakamura Y
- Subjects
- Cell- and Tissue-Based Therapy, Coculture Techniques, Humans, Immunotherapy, Adoptive, Lymph Nodes pathology, Lymphocytes, Lymphocytes, Tumor-Infiltrating, Receptors, Antigen, T-Cell, CD8-Positive T-Lymphocytes, Neoplasms pathology, Neoplasms therapy
- Abstract
Background: Tumor-draining lymph nodes (TDLNs) are primary sites, where anti-tumor lymphocytes are primed to tumor-specific antigens and play pivotal roles in immune responses against tumors. Although adoptive cell therapy (ACT) using lymphocytes isolated from TDLNs were reported, characterization of immune activity of lymphocytes in TDLNs to tumor cells was not comprehensively performed. Here, we demonstrate TDLNs to have very high potential as cell sources for immunotherapy., Methods: Lymphocytes from TDLNs resected during surgical operation were cultured with autologous-tumor cells for 2 weeks and evaluated tumor-reactivity by IFNγ ELISPOT assay. We investigated the commonality of T cell receptor (TCR) clonotypes expanded by the co-culture with tumor cells with those of tumor infiltrating lymphocytes (TILs)., Results: We found that that TCR clonotypes of PD-1-expressing CD8
+ T cells in lymph nodes commonly shared with those of TILs in primary tumors and lymphocytes having tumor-reactivity and TCR clonotypes shared with TILs could be induced from non-metastatic lymph nodes when they were co-cultured with autologous tumor cells., Conclusion: Our results imply that tumor-reactive effector T cells were present even in pathologically non-metastatic lymph nodes and could be expanded in vitro in the presence of autologous tumor cells and possibly be applied for ACT., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
43. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
- Author
-
Nakano K, Koh Y, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Wang C, Ishizuya Y, Yamamoto Y, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Kiyotani K, Katayama K, Yamaguchi R, Imoto S, Imamura R, Nonomura N, and Uemura M
- Subjects
- Biomarkers, Tumor genetics, Humans, Neoplasm, Residual, Prognosis, Carcinoma, Transitional Cell genetics, Circulating Tumor DNA genetics, Urinary Bladder Neoplasms genetics
- Abstract
Perioperative systemic chemotherapy improves the prognosis of upper tract urothelial carcinoma (UTUC). The first objective of this study was to verify whether perioperative circulating tumor DNA (ctDNA) analysis using a pan-cancer gene panel and next-generation sequencing could identify patients with poor prognosis who require perioperative chemotherapy. Second, we investigated whether ctDNA is useful for minimal residual disease (MRD) detection and treatment monitoring in UTUC. This study included 50 patients with untreated UTUC, including 43 cases of localized UTUC. We performed targeted ultradeep sequencing of plasma cell-free DNA (cfDNA) and buffy coat DNA and whole-exome sequencing of cancer tissues, allowing exclusion of possible false positives. We attempted to stratify the prognosis according to the perioperative ctDNA levels in patients with localized UTUC. In patients with metastatic UTUC, ctDNA was evaluated before, during, and after systemic treatment. In total, 23 (46%) of 50 patients with untreated UTUC were ctDNA positive, and 17 (40%) of 43 patients with localized UTUC were ctDNA positive. Of the detected TP53 mutations, 19% were false positives due to clonal hematopoiesis of indeterminate potential. Among preoperative risk factors, only the preoperative ctDNA fraction>2% was a significant and independent risk factor associated with worse recurrence-free survival (RFS). Furthermore, the existence of ctDNA early points after the operation was significantly associated with worse RFS, suggesting the presence of MRD. ctDNA also showed a potential as a real-time marker for systemic therapy in patients with metastatic UTUC. Detection of ctDNA may indicate potential metastasis and guide decisions on perioperative chemotherapy., (© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2022
- Full Text
- View/download PDF
44. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy.
- Author
-
Nagayama S, Low SK, Kiyotani K, and Nakamura Y
- Abstract
In the field of colorectal cancer (CRC) treatment, diagnostic modalities and chemotherapy regimens have progressed remarkably in the last two decades. However, it is still difficult to identify minimal residual disease (MRD) necessary for early detection of recurrence/relapse of tumors and to select and provide appropriate drugs timely before a tumor becomes multi-drug-resistant and more aggressive. We consider the leveraging of in-depth genomic profiles of tumors as a significant breakthrough to further improve the overall prognosis of CRC patients. With the recent technological advances in methodologies and bioinformatics, the genomic profiles can be analyzed profoundly without delay by blood-based tests-'liquid biopsies'. From a clinical point of view, a minimally-invasive liquid biopsy is thought to be a promising method and can be implemented in routine clinical settings in order to meet unmet clinical needs. In this review, we highlighted clinical usefulness of liquid biopsies in the clinical management of CRC patients, including cancer screening, detection of MRD, selection of appropriate molecular-targeted drugs, monitoring of the treatment responsiveness, and very early detection of recurrence/relapse of the disease. In addition, we addressed a possibility of adoptive T cell therapies and a future personalized immunotherapy based on tumor genome information.
- Published
- 2021
- Full Text
- View/download PDF
45. Immunogenomics in personalized cancer treatments.
- Author
-
Kiyotani K, Toyoshima Y, and Nakamura Y
- Subjects
- Humans, Neoplasms genetics, Neoplasms immunology, Neoplasms pathology, Tumor Microenvironment, Genetic Therapy, Genomics, Immunotherapy, Neoplasms therapy, Precision Medicine
- Abstract
Recent advances in next-generation sequencing technologies have led to significant improvements in cancer genomic research and cancer treatment. Through the use of comprehensive cancer genome data, precision medicine has become more of a reality; albeit, at present, only ~10-15% of patients can benefit from current genomic testing practices. Improvements in cancer genome analyses have contributed to a better understanding of antitumor immunity and have provided solutions for targeting highly cancer-specific neoantigens generated from somatic mutations in individual patients. Since then, numerous studies have demonstrated the importance of neoantigens and neoantigen-reactive T cells in the tumor microenvironment and how their presence influences the beneficial responses associated with various cancer immunotherapies, including immune checkpoint inhibitor therapy. Indeed, cancer immunotherapies that explicitly target neoantigens specific to individual cancer patients would lead to the ultimate form of cancer precision medicine. For this to be realized, several issues would need to be overcome, including the accurate prediction and selection of neoantigens that can induce cytotoxic T cells in individual patients. The precise prediction of target neoantigens will likely accelerate the development of personalized immunotherapy including cancer vaccines and T-cell receptor-engineered T-cell therapy for patients with cancer., (© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.)
- Published
- 2021
- Full Text
- View/download PDF
46. Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.
- Author
-
Mori S, Gotoh O, Kiyotani K, and Low SK
- Subjects
- Carcinogenesis genetics, Female, Humans, Genital Neoplasms, Female genetics, Genomics, Mutation
- Abstract
There are numerous histological subtypes (histotypes) of gynecological malignancies, with each histotype considered to largely reflect a feature of the "cell of origin," and to be tightly linked with the clinical behavior and biological phenotype of the tumor. The recent advances in massive parallel sequencing technologies have provided a more complete picture of the range of the genomic alterations that can persist within individual tumors, and have highlighted the types and frequencies of driver-gene mutations and molecular subtypes often associated with these histotypes. Several large-scale genomic cohorts, including the Cancer Genome Atlas (TCGA), have been used to characterize the genomic features of a range of gynecological malignancies, including high-grade serous ovarian carcinoma, uterine corpus endometrial carcinoma, uterine cervical carcinoma, and uterine carcinosarcoma. These datasets have also been pivotal in identifying clinically relevant molecular targets and biomarkers, and in the construction of molecular subtyping schemes. In addition, the recent widespread use of clinical sequencing for the more ubiquitous types of gynecological cancer has manifested in a series of large genomic datasets that have allowed the characterization of the genomes, driver mutations, and histotypes of even rare cancer types, with sufficient statistical power. Here, we review the field of gynecological cancer, and seek to describe the genomic features by histotype. We also will demonstrate how these are linked with clinicopathological attributes and highlight the potential tumorigenic mechanisms., (© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.)
- Published
- 2021
- Full Text
- View/download PDF
47. Personalized immunotherapy in cancer precision medicine.
- Author
-
Kiyotani K, Toyoshima Y, and Nakamura Y
- Abstract
With the significant advances in cancer genomics using next-generation sequencing technologies, genomic and molecular profiling-based precision medicine is used as a part of routine clinical test for guiding and selecting the most appropriate treatments for individual cancer patients. Although many molecular-targeted therapies for a number of actionable genomic alterations have been developed, the clinical application of such information is still limited to a small proportion of cancer patients. In this review, we summarize the current status of personalized drug selection based on genomic and molecular profiling and highlight the challenges how we can further utilize the individual genomic information. Cancer immunotherapies, including immune checkpoint inhibitors, would be one of the potential approaches to apply the results of genomic sequencing most effectively. Highly cancer-specific antigens derived from somatic mutations, the so-called neoantigens, occurring in individual cancers have been in focus recently. Cancer immunotherapies, which target neoantigens, could lead to a precise treatment for cancer patients, despite the challenge in accurately predicting neoantigens that can induce cytotoxic T cells in individual patients. Precise prediction of neoantigens should accelerate the development of personalized immunotherapy including cancer vaccines and T-cell receptor-engineered T-cell therapy for a broader range of cancer patients., Competing Interests: Kazuma Kiyotani is a scientific advisor of Cancer Precision Medicine, Inc. Yusuke Nakamura is a stockholder and a scientific advisor of OncoTherapy Science, Inc., (Copyright © 2021 Cancer Biology & Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
48. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
- Author
-
Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, and Nakamura Y
- Subjects
- Adult, Aged, Female, Humans, Immunotherapy, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Antigens, Neoplasm administration & dosage, Cancer Vaccines therapeutic use, Dendritic Cells, Neoplasms therapy, Peptides administration & dosage
- Abstract
Background/aim: Neoantigens are tumor-specific antigens that emerge due to gene mutations in tumor cells, and are highly antigenic epitopes that escape central immune tolerance in the thymus, making cancer vaccine therapy a desirable option., Patients and Methods: Tumor neoantigens were predicted in 17 patients with advanced cancer. They were resistant to the standard treatment regime, and their synthetic peptides were pulsed to the patient's monocyte-derived dendritic cells (DCs), and administered to the patient's lymph nodes via ultrasound., Results: Some patients showed sustained tumor shrinkage after this treatment, while some did not respond, showing no ELISpot reaction. Although the number of mutations and the predicted neoantigen epitopes differed between patients, the clinical effect depended more on the presence or absence of an immune response after vaccination rather than the number of neoantigens., Conclusion: Intranodal neoantigen peptide-pulsed DC vaccine administration therapy has clinical and immunological efficacy and safety., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
- Author
-
Morisaki T, Hikichi T, Onishi H, Morisaki T, Kubo M, Hirano T, Yoshimura S, Kiyotani K, and Nakamura Y
- Subjects
- Aged, Antigen Presentation, Antigens, Neoplasm immunology, Ascites immunology, CA-125 Antigen blood, Drug Resistance, Neoplasm, Enzyme-Linked Immunospot Assay, Epitopes, T-Lymphocyte immunology, Female, Humans, Ovarian Neoplasms immunology, Peptides immunology, Tumor Burden, Vaccination, Ascites therapy, Cancer Vaccines immunology, Dendritic Cells immunology, Immunotherapy methods, Lymphocytes, Tumor-Infiltrating immunology, Ovarian Neoplasms therapy, Sentinel Lymph Node immunology, T-Lymphocytes immunology
- Abstract
Chemorefractory ovarian cancer has limited therapeutic options. Hence, new types of treatment including neoantigen-specific immunotherapy need to be investigated. Neoantigens represent promising targets for personalized cancer immunotherapy. We here describe the clinical and immunological effects of a neoantigen peptide-loaded DC-based immunotherapy in a patient with recurrent and chemoresistant ovarian cancer. A 71-year-old female patient with chemorefractory ovarian cancer and malignant ascites received intranodal vaccination of DCs loaded with four neoantigen peptides that were predicted by our immunogenomic pipeline. Following four rounds of vaccinations with this therapy, CA-125 levels were remarkably declined and tumor cells in the ascites were also decreased. Concordantly, the tumor-related symptoms such as respiratory discomfort improved without any adverse reactions. The reactivity against one HLA-A2402-restricted neoantigen peptide derived from a mutated PPM1 F protein was detected in lymphocytes from peripheral blood by IFN-γ ELISPOT assay. Furthermore, the neoantigen (PPM1 F mutant)-specific TCRs were detected in the tumor-infiltrating T lymphocytes post-vaccination. Our results showed that vaccination with intranodal injection of neoantigen peptide-loaded DCs may have clinical and immunological impacts on cancer treatment.
- Published
- 2021
- Full Text
- View/download PDF
50. Neoantigens elicit T cell responses in breast cancer.
- Author
-
Morisaki T, Kubo M, Umebayashi M, Yew PY, Yoshimura S, Park JH, Kiyotani K, Kai M, Yamada M, Oda Y, Nakamura Y, Morisaki T, and Nakamura M
- Subjects
- Adult, Aged, Antigens, Neoplasm genetics, Breast Neoplasms genetics, Dendritic Cells immunology, Female, Humans, Middle Aged, Exome Sequencing, Antigens, Neoplasm immunology, Breast Neoplasms immunology, Immunity, Cellular, Lymphocytes, Tumor-Infiltrating immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Neoantigens are tumour-specific antigens that arise from non-synonymous mutations in tumour cells. However, their effect on immune responses in the tumour microenvironment remains unclear in breast cancer. We performed whole exome and RNA sequencing of 31 fresh breast cancer tissues and neoantigen prediction from non-synonymous single nucleotide variants (nsSNVs) among exonic mutations. Neoantigen profiles were determined by predictive HLA binding affinity (IC
50 < 500 nM) and mRNA expression with a read count of ≥ 1. We evaluated the association between neoantigen load and expression levels of immune-related genes. Moreover, using primary tumour cells established from pleural fluid of a breast cancer patient with carcinomatous pleurisy, we induced cytotoxic T lymphocytes (CTLs) by coculturing neoantigen peptide-pulsed dendritic cells (DCs) with autologous peripheral lymphocytes. The functions of CTLs were examined by cytotoxicity and IFN-γ ELISpot assays. Neoantigen load ranged from 6 to 440 (mean, 95) and was positively correlated to the total number of nsSNVs. Although no associations between neoantigen load and mRNA expression of T cell markers were observed, the coculture of neoantigen-pulsed DCs and lymphocytes successfully induced CTLs ex vivo. These results suggest that neoantigen analysis may have utility in developing strategies to elicit T cell responses.- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.